PUM2 and glioblastoma: Our results indicate that activities of PUM2 are critical molecular characteristics of glioblastoma cells and BTG1 is involved in PUM2 downstream cellular pathways, suggesting PUM2 and BTG1 can be the potential pharmacotherapeutic targets in treatment of glioblastoma.